← Leaderboards
Mateusz Opyrchal
Indiana University Indianapolis
$1,160,437
Attributed
$2,800,636
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,800,636 · 4
By mechanism
R01$2,704,939 · 2
P30$95,697 · 2
Top collaborators
- Xinna Zhang5 shared
- Baohua Zhou3 shared
Most similar at Indiana University Indianapolis
Same institution · by research overlap
- Mark H. Kaplan$27,781,093
- Stanley M Spinola$14,547,790
- William J Sullivan Jr$13,937,697
- Xinna Zhang$3,467,211
- Mithun Sinha$1,816,579
Others in their field
Other Rising Stars on “Research Personnel”
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
- Rebecca Montalvan · Westat, Inc.$86,600,000
- Gary Mays · Axle Informatics, Llc$58,758,787
- Mari Ostendorf · University Of Washington$51,931,230
- Jessica Ellis · Technical Resources International, Inc.$45,038,640
- Jeffrey Leintz · National Opinion Research Center$39,962,545
Research focus
Research PersonnelCancer BiologyTumorCancer TherapyPublic HealthCellsResistanceOrganoidsSuccessScienceProgramsCd8-Positive T-LymphocytesImmune SystemRegulatory T-LymphocyteBioinformaticsAdoptive Cell TransfersImmuneImmune Checkpoint InhibitorMediatingCancer ImmunotherapyImmunologyNeoplastic CellT-LymphocyteTumor Promotion
Grant awards (7)
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy$585,212
R01 · FY2025 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy$501,827
R01 · FY2025 · CA
Experimental and Developmental Therapeutics$63,896
P30 · FY2025 · CA · contact PI
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy$555,952
R01 · FY2024 · CA
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy$476,736
R01 · FY2024 · CA
Targeting FOXP3 mRNA splicing for breast cancer immunotherapy$585,212
R01 · FY2023 · CA
Experimental and Developmental Therapeutics Program$31,801
P30 · FY2023 · CA · contact PI